Green Tea

Purported Benefits, Side Effects & More

Green Tea

Purported Benefits, Side Effects & More
Green Tea

Common Names

  • Chinese tea
  • Green tea extract
  • Green tea polyphenols
  • Epigallocatechin gallate (EGCG)

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.

What is it?

Green tea is a drink made from the Camellia sinensis plant. Fresh leaves are cut from this plant and steamed to make the tea.

You can drink green tea or take it orally (by mouth) in a pill or tablet as a dietary supplement. You can also use green tea extract on your skin as a cream.

What are the potential uses and benefits?

Green tea is used to:

  • Prevent heart disease
  • Help lose weight

Green tea also has other uses that haven’t been studied by doctors to see if they work.

It’s generally safe to drink green tea and use it in food. Talk with your healthcare providers before taking green tea supplements. Herbal supplements are stronger than the herbs you would use in cooking.

Supplements can also interact with some medications and affect how they work. For more information, read the “What else do I need to know?” section below.

What are the side effects?

Side effects of taking green tea supplements may include:

  • Nausea (feeling like you’re going to throw up)
  • Stomach pain
  • Drinking too much green tea can disrupt your sleep, and can also give you headaches
What else do I need to know?
  • Talk to your doctor if you’re taking iron supplements. Green tea can affect the way iron is absorbed in the body. 
  • Don’t drink green tea if you’re pregnant or breastfeeding. Green tea has caffeine in it that may cause your baby to have trouble sleeping.
  • Avoid drinking green tea if you have a stomach ulcer (sore in the lining of your stomach). Green tea may make your ulcer worse.
  • Green tea may lower the risk of some types of cancers, but there is no clear evidence of its effectiveness.

For Healthcare Professionals

Scientific Name
Camellia sinensis
Clinical Summary

Green tea is a beverage derived from the unfermented leaves of a plant native to Asia. Green tea extract is marketed as an antioxidant and dietary supplement to support cardiovascular, metabolic, cognitive, and cellular health. Active constituents include the polyphenol epigallocatechin-3-gallate (EGCG), caffeine, and theanine.

Green tea consumption may reduce risk for dementia (1), hypertension (2), cardiovascular disease (63), small vessel stroke (71), and all-cause but not cancer-related mortality (3) (4). Data are mixed on whether it can reduce risk of gastric and esophageal cancers (5) (6) (7). Other findings suggest preventive benefits with green tea and its active compounds against oral premalignant lesions (8) and for those at high risk of developing liver or colorectal cancers (9) (10) but not colorectal adenomas (64). There is no association between green tea and risk for malignant lymphoma or multiple myeloma (11), but intake may reduce risk for myelodysplastic syndrome (12) and kidney cancer (65).

In prostate cancer patients, a blend of green tea, pomegranate, broccoli, and curcumin had a protective effect following post-radical treatment (13). Green tea consumption also decreased PSA levels in patients prior to prostatectomy (14). However, combination supplementation with the highest nontoxic doses of green tea catechins, selenium, and lycopene was associated with an elevated incidence of prostate cancer in high-risk patients (15), and long-term intake of an EGCG product did not reduce prostate cancer risk (16).

Other limited data suggest oral EGCG may induce a biologic response in patients with chronic lymphocytic leukemia (17) or reduce radiation-induced esophagitis in lung cancer patients (18), but did not prevent recurrence in advanced ovarian cancer (19). Topical EGCG may help relieve radiation-induced dermatitis in breast cancer patients (20) (21), but these results are also preliminary.    

Green tea reduced the risk of recurrence in breast cancer patients  (72), but regular consumption may elevate the risk in some postmenopausal women (22). Future studies are needed to resolve this ambiguity and to determine whether there are potential benefits on overall cancer risk (23).

Additional studies suggest positive effects of green tea on lipid profiles (73) and glycemic control in type-2 diabetes patients (66), for weight reduction in  obese/overweight adults (74) and in women with polycystic ovary syndrome (67), for sarcopenia in older adults (75), and for patients with acne (76).

Moderate green tea consumption was not associated with increased risk of kidney stone formation (24), but the caffeinated form may cause insomnia and nausea. Animal models suggest use of green tea extract during fasting may increase toxicity risk (25). Clinical data show that EGCG 200 mg twice daily for one year is safe (26), whereas 800 mg daily was associated with elevated liver enzymes (27).

Purported Uses and Benefits
  • Cardiovascular support
  • Weight loss
Mechanism of Action

Green tea may confer cardiovascular protection by increasing HDL and lowering LDL and triglyceride levels (28). Blood pressure modulation may be mediated by EGCG which induces NO production that results in vasodilation (29). Neurocognitive benefits with green tea extract may occur from enhanced brain connectivity during working memory processing (30), and EGCG may inhibit tau protein aggregation to reduce toxicity in neuronal model cells (31).

Chemopreventive properties are attributed to polyphenols, particularly EGCG which may inhibit enzymes involved in cell replication and DNA synthesis (32). In vitro data suggest concentrations of 30 mcg/mL of EGCG and EGC inhibit arachidonic acid metabolism by 30–75%, which may reduce colon cancer risk (33). Other studies in human colon cancer cell lines suggest EGCG inhibits topoisomerase I but not II (34). It also inhibited DNA replication in leukemia cancer cell lines (35), and modulated VEGF leading to apoptosis in leukemic cells (36). An early animal study identified caffeine in green tea as an important component for inhibition of UVB light-induced carcinogenesis (37).

  • The United States Pharmacopeia included this cautionary labeling requirement in its Powdered Decaffeinated Green Tea Extract monograph (38):
    Do not take on an empty stomach. Take with food. Do not use if you have a liver problem and discontinue use and consult a healthcare practitioner if you develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes).”  
Adverse Reactions
  • Green tea is generally considered safe, but excessive consumption can disrupt sleep and cause headaches because of its caffeine content.
  • EGCG 200 mg twice daily with food for 1 year appeared to be safe in men at higher risk for prostate cancer (26).

Reactions with high doses reported in clinical trials

  • Nausea, abdominal pain, and transaminitis: With EGCG 2000 mg twice daily (17).
  • Weight gain, indigestion, insomnia: With EGCG 1200 mg daily (39).
  • Elevated liver enzymes: With green tea extract 800 mg (27) or EGCG 843 mg–1600 mg (39) (40) daily.
  • Rectal bleeding: With EGCG 800mg daily (39).

Case reports

  • Hepatotoxicity: With green tea extracts containing high EGCG levels (41) (42) (43) (44) (45) (68).
  • Pruritic swelling/darkening of lower lip: In a 40-year-old woman following excessive long-term green tea consumption (46).
  • Thrombotic thrombocytopenic purpura: In a 38-year-old woman after taking a green tea supplement for weight loss (47).
  • Autoimmune hepatitis: In a 42-year-old female with type-2 diabetes mellitus after consuming a green tea product for weight loss (69).
Herb-Drug Interactions
  • Anticoagulants / antiplatelets: Theoretically, consuming large amounts of green tea (.5–1 gallon/day) may provide enough vitamin K to antagonize effects of these agents (48).
  • Bortezomib: EGCG and other polyphenols can inhibit the therapeutic effect of bortezomib and other boronic acid-based proteasome inhibitors (49).
  • Tamoxifen: EGCG increased oral bioavailability of tamoxifen, increasing the potential for interactions (50).
  • Verapamil: EGCG increased verapamil bioavailability, likely via P-glycoprotein inhibition (51).
  • Irinotecan: A study found EGCG to inhibit transport of irinotecan and its metabolite SN-38 into biliary elimination, resulting in their prolonged half-life which can increase toxicity (52).
  • CYP3A4 substrates: Green tea extract inhibits CYP 3A4 and can affect the intracellular concentration of drugs metabolized by this enzyme (41) (53) (54).
  • UGT substrates: Green tea modulates UGT enzymes in vitro and can increase the side effects of drugs metabolized by them (55).
  • Acetaminophen: Green tea increased acetaminophen-induced hepatotoxicity in mice when administered following acetaminophen (56).
  • Nadolol: Green tea extract inhibits OATP1A2 transporter and can reduce the absorption and plasma concentration of substrate drugs like nadolol (57).
  • Palbociclib: The bioavailability of palbociclib decreased following administration of green tea extract in a murine model (58). Clinical relevance has yet to be determined.
  • Ticagrelor: Green tea polyphenols inhibited ticagrelor metabolism in vitro. Clinical relevance has yet to be determined (59).
  • Atorvastatin: Green tea limited hepatic drug uptake and increased plasma exposure to atorvastatin in a murine model. Clinical significance is not known (60).
  • Rosuvastatin: Repeated administration of green tea extract significantly lowered systemic exposure of rosuvastatin in healthy volunteers (61).
  • Ziprasidone: A 23-year-old man stable for several months on ziprasidone became psychotic within days following use of a green tea extract for weight loss (62).
  • Nintedanib: A clinical study of patients with pulmonary fibrosis found concomitant use of green tea to lower bioavailability of nintedanib by 21% (70).
  • Raloxifene: Concurrent use of green tea decreased systemic exposure of raloxifene in a study of healthy adults (77).
  • Nadolol: A 37-year-old woman treated with high-dose nadolol for catecholaminergic polymorphic ventricular tachycardia experienced a relapse of cardiac rhythm disorders, and testing showed a dramatic decrease in plasma nadolol concentrations, following green tea consumption. Symptoms resolved after stopping intake (78).
Dosage (OneMSK Only)
  1. Matsushita N, Nakanishi Y, Watanabe Y, et al. Association of coffee, green tea, and caffeine with the risk of dementia in older Japanese people. J Am Geriatr Soc. Dec 2021;69(12):3529-3544.
  2. Yang YC, Lu FH, Wu JS, et al. The protective effect of habitual tea consumption on hypertension. Arch Intern Med. Jul 26 2004;164(14):1534-1540.
  3. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. Sep 13 2006;296(10):1255-1265.
  4. Shin S, Lee JE, Loftfield E, et al. Coffee and tea consumption and mortality from all causes, cardiovascular disease and cancer: a pooled analysis of prospective studies from the Asia Cohort Consortium. Int J Epidemiol. May 9 2022;51(2):626-640.
  5. Sun CL, Yuan JM, Lee MJ, et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis. Sep 2002;23(9):1497-1503.
  6. Nechuta S, Shu XO, Li HL, et al. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women’s Health Study. Am J Clin Nutr. Nov 2012;96(5):1056-1063.
  7. Myung SK, Bae WK, Oh SM, et al. Green tea consumption and risk of stomach cancer: a meta-analysis of epidemiologic studies. Int J Cancer. Feb 1 2009;124(3):670-677.
  8. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). Nov 2009;2(11):931-941.
  9. Xue KS, Tang L, Cai Q, et al. Mitigation of Fumonisin Biomarkers by Green Tea Polyphenols in a High-Risk Population of Hepatocellular Carcinoma. Sci Rep. Dec 2 2015;5:17545.
  10. Shin CM, Lee DH, Seo AY, et al. Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial. Clin Nutr. Apr 2018;37(2):452-458.
  11. Ugai T, Matsuo K, Sawada N, et al. Coffee and Green Tea Consumption and Subsequent Risk of Malignant Lymphoma and Multiple Myeloma in Japan: The Japan Public Health Center-based Prospective Study. Cancer Epidemiol Biomarkers Prev. Aug 2017;26(8):1352-1356.
  12. Liu P, Zhang M, Jin J, et al. Tea consumption reduces the risk of de novo myelodysplastic syndromes. Leuk Res. Feb 2015;39(2):164-169.
  13. Thomas R, Williams M, Sharma H, et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis. Jun 2014;17(2):180-186.
  14. Henning SM, Wang P, Said JW, et al. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. Apr 1 2015;75(5):550-559.
  15. Gontero P, Marra G, Soria F, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”? Prostate. Aug 1 2015;75(11):1177-1186.
  16. Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). Oct 2015;8(10):879-887.
  17. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. Jan 15 2013;119(2):363-370.
  18. Zhao H, Xie P, Li X, et al. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiother Oncol. Mar 2015;114(3):351-356.
  19. Trudel D, Labbé DP, Araya-Farias M, et al. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. Nov 2013;131(2):357-361.
  20. Zhu W, Jia L, Chen G, et al. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy. Oncotarget. Jul 26 2016;7(30):48607-48613.
  21. Zhao H, Zhu W, Jia L, et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br J Radiol. 2016;89(1058):20150665.
  22. Li M, Tse LA, Chan WC, et al. Evaluation of breast cancer risk associated with tea consumption by menopausal and estrogen receptor status among Chinese women in Hong Kong. Cancer Epidemiol. Feb 2016;40:73-78.
  23. Filippini T, Malavolti M, Borrelli F, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev. Mar 2 2020;3(3):Cd005004.
  24. Barghouthy Y, Corrales M, Doizi S, et al. Tea and coffee consumption and the risk of urinary stones-a systematic review of the epidemiological data. World J Urol. Aug 2021;39(8):2895-2901.
  25. Wu KM, Yao J, Boring D. Green tea extract-induced lethal toxicity in fasted but not in nonfasted dogs. Int J Toxicol. Feb 2011;30(1):19-20.
  26. Kumar NB, Pow-Sang J, Spiess PE, et al. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. Oct 25 2016;7(43):70794-70802.
  27. Yu Z, Samavat H, Dostal AM, et al. Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States. Cancer Prev Res (Phila). Oct 2017;10(10):571-579.
  28. Maron DJ, Lu GP, Cai NS, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. Jun 23 2003;163(12):1448-1453.
  29. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. Feb 13 2004;279(7):6190-6195.
  30. Schmidt A, Hammann F, Wölnerhanssen B, et al. Green tea extract enhances parieto-frontal connectivity during working memory processing. Psychopharmacology (Berl). Oct 2014;231(19):3879-3888.
  31. Wobst HJ, Sharma A, Diamond MI, et al. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. Jan 2 2015;589(1):77-83.
  32. Yang CS, Prabhu S, Landau J. Prevention of carcinogenesis by tea polyphenols. Drug Metab Rev. Aug-Nov 2001;33(3-4):237-253.
  33. Hong J, Smith TJ, Ho CT, et al. Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues. Biochem Pharmacol. Nov 1 2001;62(9):1175-1183.
  34. Berger SJ, Gupta S, Belfi CA, et al. Green tea constituent (—)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun. Oct 19 2001;288(1):101-105.
  35. Smith DM, Dou QP. Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med. Jun 2001;7(6):645-652.
  36. Lee YK, Bone ND, Strege AK, et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. Aug 1 2004;104(3):788-794.
  37. Huang MT, Xie JG, Wang ZY, et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res. Jul 1 1997;57(13):2623-2629.
  38. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicol Rep. 2020;7:386-402.
  39. Crew KD, Brown P, Greenlee H, et al. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). Sep 2012;5(9):1144-1154.
  40. Dostal AM, Samavat H, Bedell S, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. Food Chem Toxicol. Sep 2015;83:26-35.
  41. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. Apr 2009;65(4):331-341.
  42. Vanstraelen S, Rahier J, Geubel AP. Jaundice as a misadventure of a green tea (Camellia sinensis) lover : a case report. Acta Gastroenterol Belg. Oct-Dec 2008;71(4):409-412.
  43. Verhelst X, Burvenich P, Van Sassenbroeck D, et al. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia sinensis). Acta Gastroenterol Belg. Apr-Jun 2009;72(2):262-264.
  44. Fernández J, Navascués C, Albines G, et al. Three cases of liver toxicity with a dietary supplement intended to stop hair loss. Rev Esp Enferm Dig. Dec 2014;106(8):552-555.
  45. Percevault S, Charpiat B, Lebossé F, et al. Green tea and hepatoxicity: Two case reports. Therapie. Sep-Oct 2022;77(5):620-622.
  46. Lee JI, Cho BK, Ock SM, et al. Pigmented contact cheilitis: from green tea? Contact Dermatitis. Jan 2010;62(1):60-61.
  47. Liatsos GD, Moulakakis A, Ketikoglou I, et al. Possible green tea-induced thrombotic thrombocytopenic purpura. Am J Health Syst Pharm. Apr 1 2010;67(7):531-534.
  48. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. Apr 1999;33(4):426-428.
  49. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. Jun 4 2009;113(23):5927-5937.
  50. Shin SC, Choi JS. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs. Aug 2009;20(7):584-588.
  51. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos. Mar 2009;30(2):90-93.
  52. Lin LC, Wang MN, Tsai TH. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact. Aug 11 2008;174(3):177-182.
  53. Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Metabol Drug Interact. 2009;24(1):17-35.
  54. Darweesh RS, El-Elimat T, Zayed A, et al. The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats. BMC Pharmacol Toxicol. Nov 16 2020;21(1):77.
  55. Mohamed ME, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. Mar 2011;77(4):311-321.
  56. Salminen WF, Yang X, Shi Q, et al. Green tea extract can potentiate acetaminophen-induced hepatotoxicity in mice. Food Chem Toxicol. May 2012;50(5):1439-1446.
  57. Misaka S, Yatabe J, Müller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. Apr 2014;95(4):432-438.
  58. Paul D, Surendran S, Chandrakala P, et al. An assessment of the impact of green tea extract on palbociclib pharmacokinetics using a validated UHPLC-QTOF-MS method. Biomed Chromatogr. Apr 2019;33(4):e4469.
  59. Wang ZT, Xue Y, Sun H, et al. Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. J Food Sci. Apr 2020;85(4):1285-1291.
  60. Yao HT, Hsu YR, Li ML. Beverage-Drug Interaction: Effects of Green Tea Beverage Consumption on Atorvastatin Metabolism and Membrane Transporters in the Small Intestine and Liver of Rats. Membranes (Basel). Sep 14 2020;10(9).
  61. Zeng W, Hu M, Lee HK, et al. Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers. Front Nutr. 2022;9:850318.
  62. Mahgoub Y, Madden K, Xia T. When Green Becomes Mean: Green Tea Extract Reduces Ziprasidone’s Effect and Causes Psychosis. Prim Care Companion CNS Disord. Jan 23 2020;22(1).
  63. Zamani M, Kelishadi MR, Ashtary-Larky D, et al. The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. Front Nutr. 2023 Jan 10;9:1084455.
  64. Seufferlein T, Ettrich TJ, Menzler S, et al. Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. Am J Gastroenterol. 2022 Jun 1;117(6):884-894.
  65. Chen Y, Abe SK, Inoue M, Yamaji T, et al. Green tea and coffee consumption and risk of kidney cancer in Japanese adults. Sci Rep. 2022 Nov 24;12(1):20274.
  66. Wang P, Ma XM, Geng K, et al. Effects of Camellia tea and herbal tea on cardiometabolic risk in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022 Nov;36(11):4051-4062.
  67. Colonetti L, Grande AJ, Toreti IR, et al. Green tea promotes weight loss in women with polycystic ovary syndrome: Systematic review and meta-analysis. Nutr Res. 2022 Aug;104:1-9.
  68. Assis MH, Alves BC, Luft VC, Dall’alba V. LIVER INJURY INDUCED BY HERBAL AND DIETARY SUPPLEMENTS: A POOLED ANALYSIS OF CASE REPORTS. Arq Gastroenterol. 2022 Oct-Dec;59(4):522-530.
  69. Sacoto DH, Turbay V, Sandhu J, Chaudhari S, Cosico J. The Threat of Weight-Loss Over the Counter Supplements: A Case of Camellia Sinensis Autoimmune Hepatitis. Cureus. 2023 Mar 11;15(3):e36023.
  70. Veerman GDM, van der Werff SC, Koolen SLW, et al. The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis. Biomed Pharmacother. 2022 Jul;151:113101.
  71. Deng X, Lai R, Zhu J, et al. Causal Association between Tea Intake and Acute Cerebrovascular Events: A Multivariate Mendelian Randomized Study in European Populations.  J Nutr. 2024 Jan;154(1):79-86.
  72. van Die MD, Bone KM, Visvanathan K, et al. Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.  JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad104.
  73. Yazdanpanah Z, Salehi-Abargouei A, Mozaffari Z, Hemayati R. The effect of green tea (Camellia sinensis) on lipid profiles and renal function in people with type 2 diabetes and nephropathy: a randomized controlled clinical trial.  Front Nutr. 2023 Dec 14;10:1253275. 
  74. Shahinfar H, Jayedi A, Torabynasab K, Payandeh N, et al. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: A systematic review and network meta-analysis of 111 randomized clinical trials.  Pharmacol Res. 2023 Oct;196:106944.
  75. Wu C, Suzuki K. The Effects of Flavonoids on Skeletal Muscle Mass, Muscle Function, and Physical Performance in Individuals with Sarcopenia: A Systematic Review of Randomized Controlled Trials. Nutrients. 2023 Sep 7;15(18):3897. 
  76. Shields A, Ly S, Wafae B, et al. Safety and Effectiveness of Oral Nutraceuticals for Treating Acne: A Systematic Review.  JAMA Dermatol. 2023 Dec 1;159(12):1373-1382. 
  77. Clarke JD, Judson SM, Tian DD, et al. Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants.  Clin Transl Sci. 2023 Oct;16(10):1779-1790.
  78. Facile A, Deliniere A, Auffret M, Vial T, Citterio-Quentin A, Chevalier P, Grenet G. Green tea and nadolol interaction: A risk of therapeutic inefficiency, a case report and extensive review.  Therapie. 2023 Oct 19:S0040-5957(23)00144-0.
Email your questions and comments to [email protected].

Last Updated